Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Renvistobart · COM701, BMS-986207

Monoclonal antibody · Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) · developed by Compugen

Phase 1/2 Most advanced trial (none active)
CGEN Developer
1 Registered trials

What is Renvistobart?

Renvistobart is a human monoclonal antibody that binds TIGIT, an immune inhibitory receptor expressed on tumor-infiltrating T lymphocytes and other immune cells. By blocking TIGIT's interaction with CD112 and CD155, it enhances CD226-mediated signaling in NK cells and CD8+ T cells. It is studied in endometrial, ovarian and head and neck cancers and solid tumors, in combination with nivolumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
COM701, BMS-986207
Drug type
Monoclonal antibody
Targets
T-cell immunoreceptor with Ig and ITIM domains (TIGIT), CD112 (nectin-2) (NECTIN2) (binding partner it blocks), CD155 (poliovirus receptor) (PVR) (binding partner it blocks)
Mechanism
Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT)
Pathways
TIGIT-CD155/CD112 interaction blockade, CD226 (DNAM-1) costimulatory signaling, T-cell activation and proliferation
Therapy area
Oncology
Developer
Compugen Ltd (CGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
81J55YFQ16

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04570839 Phase 1/2 Endometrial Neoplasms Completed CGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial NeoplasmsHead and Neck CancerOvarian CancerSolid Tumor

Other drugs acting on TIGIT

More from Compugen

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEN page.

Follow CGEN, the company behind Renvistobart

See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.